In this free webinar, gain insight into new changes in molecular reclassification of hematologic malignancies and their effects in precision medicine. Attendees will learn about the use of molecular ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta ...

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non–Small-Cell Lung Cancer From the Perspective of Spanish Reference ...

The MarketWatch News Department was not involved in the creation of this content.-- The agreement aims to expand access to the therapy in Brazil; -- The Technology is for patients ...

- Nine abstracts across Takeda’s hematology portfolio and pipeline demonstrate Takeda’s commitment to patient-centric, innovative care that aims to drive greater treatment outcomes - Includes data ...

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases. Jennifer Vidrine, ...

Another disease-related barrier relates to the cytopenias experienced by many patients with HMs because of their disease or its treatment. Treatment of anemia and thrombocytopenia consists mainly of ...

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases. Improving end-of-life care for pediatric ...

Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...